Zenas Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Zenas Biopharma Inc (ZBIO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Zenas Biopharma Inc vs Its Competitors
- Scale: Zenas Biopharma Inc ranks #113 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Zenas Biopharma Inc accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ZBIO Sales vs. its Competitors, Q2 2026
Zenas Biopharma Inc generated 100.00 % of the combined sales of its peer group.
Zenas Biopharma Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Zenas Biopharma Inc | - | - | - | No |
| High-Confidence Competitors (1) | - | - | - | |
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ZBIO Stock Performance relative to its Competitors
ZBIO Stock Performance relative to High-Confidence Competitors
ZBIO Stock Performance relative to Similar-Size Competitors
Zenas Biopharma Inc's Comment on Competition and Industry Peers
Zenas Biopharma Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Dianthus Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Zenas Biopharma Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Zenas Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Zenas Biopharma Inc | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).